欧洲寡转移性胃食管癌的定义、诊断与治疗:Delphi共识研究
该Delphi共识研究纳入来自16个欧洲国家49个专家中心的65名 specialists,经启动会议、两轮在线问卷和共识会议,最终48名专家全程参与(总应答率71%)。共识界定寡转移性胃食管癌为转移限于1个器官且≤3个转移灶或1个区域外淋巴结站,且系统治疗后再分期无进展;同步或异时性寡转移无病间期≤2年者推荐系统治疗后重新分期考虑局部治疗,无病间期>2年者可选择 upfront 局部治疗或系统治疗后重新分期(fair agreement)。
要点
- 寡转移性胃食管癌定义为转移限于1个器官且≤3个转移灶或1个区域外淋巴结站(共识)。
- 系统治疗后再分期无进展者考虑为寡转移状态(共识)。
- 同步或异时性寡转移无病间期≤2年者,系统治疗后重新分期考虑局部治疗(共识)。
核心结论
- OMEC项目形成了欧洲多学科共识声明,用于寡转移性胃食管腺癌和鳞状细胞癌的定义、诊断和治疗,可用于标准化未来临床试验的入选标准。
研究设计与样本
- Delphi共识研究,邀请来自16个欧洲国家49个专家中心的65名胃食管癌多学科治疗专家参与,共识流程包括启动会议、2轮在线Delphi问卷和1次在线共识会议。
- Delphi问卷输入包括(1)关于寡转移性胃食管癌定义的系统综述和(2)多学科团队对真实临床病例的讨论;专家对每条陈述采用5点Likert量表评分。
- 共48名专家参与了启动会议、两轮Delphi问卷和共识会议(总应答率71%);共识程度分为无/差(<50%)、一般(50%-75%)和共识(≥75%)。
主要发现
- 寡转移性胃食管癌考虑用于转移限于1个器官且≤3个转移灶或1个区域外淋巴结站的患者(共识)。
- 寡转移性胃食管癌还考虑用于系统治疗后再分期无进展的患者(共识)。
- 对于同步或异时性寡转移且无病间期≤2年的患者,考虑系统治疗后重新分期以评估局部治疗作为治疗方式(共识)。
- 对于异时性寡转移且无病间期>2年的患者,考虑 upfront 局部治疗或系统治疗后重新分期作为治疗方式(fair agreement)。
关键数值与推荐
- 共识定义为转移限于1个器官且≤3个转移灶或1个区域外淋巴结站(共识)。
- 系统治疗后再分期无进展者考虑为寡转移状态(共识)。
- 同步或异时性寡转移无病间期≤2年者,推荐系统治疗后重新分期考虑局部治疗(共识)。
- 异时性寡转移无病间期>2年者,可选择 upfront 局部治疗或系统治疗后重新分期(fair agreement)。
临床怎么用
- 该欧洲多学科共识声明可用于标准化未来临床试验的入选标准。
- 临床中可依据共识定义(1个器官且≤3个转移灶或1个区域外淋巴结站)识别寡转移性胃食管癌患者。
- 对系统治疗后再分期无进展者,可考虑为寡转移状态。
- 同步或异时性寡转移无病间期≤2年者,共识推荐系统治疗后重新分期考虑局部治疗。
- 异时性寡转移无病间期>2年者,可选择 upfront 局部治疗或系统治疗后重新分期(fair agreement)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. METHODS: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). RESULTS: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). CONCLUSION: The OMEC project has resulted in a multidisciplinary European consensus statement for the definition, diagnosis and treatment of oligometastatic oesophagogastric adenocarcinoma and squamous cell cancer. This can be used to standardise inclusion criteria for future clinical trials.
引用
- Kroese TE, van Laarhoven HWM, Schoppman SF, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer. 2023. PMID: 36947929. doi:10.1016/j.ejca.2023.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。